Please login to the form below

Not currently logged in
Email:
Password:

DiCE Molecules adds Dr Richard Scheller to its board of directors

He currently serves as chief scientific officer at 23andMe

DiCE Molecules Dr Richard SchellerSan Francisco-based DiCE Molecules has appointed Dr Richard Scheller to its board of directors.

Dr Scheller brings nearly 20 years of leadership in drug discovery research and development to DiCE Molecules, and currently serves as chief scientific officer and head of therapeutics at 23andMe.

Prior to this, Dr Scheller spent 14 years at Roche's Genentech, the US biotechnology corporation, where he held a number of R&D roles including executive vice president of research and early development.

Between 1982 and 2001, Dr Scheller was a professor in Stanford University's department of biological sciences, and the department of molecular and cellular physiology.

Since 2004, he has served as an adjunct professor in the department of biochemistry and biophysics at the University of California, San Francisco.

Kevin Judice, president and chief executive of DiCE, said: “I have known Richard for years and had the opportunity to work with him early in my career at Genentech – he is truly a visionary and a distinguished leader in oncology, neuroscience, immunology and infectious disease drug development.

“I am delighted to have the opportunity to work with him again as a member of our board and we look forward to his guidance and leadership as we further prove out our science and bring potential drug targets into the clinic.”

7th June 2016

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Onyx Health

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....